NCT07263178Recruiting
A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
A Multi-center, Prospective, Observational Study to Assess the Treatment Patterns and Prognosis of Second and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer Who Failed First-line Palliative Chemotherapy
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 23 Nov 2025
- Start date
- 7 Nov 2025
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Diseases
- Colorectal cancer
- NCT number
- NCT07263178
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 7 Nov 2025 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has received an investigational product within 4 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
Other
- Female patients who are pregnant, have childbearing potential, or are breastfeeding.
- Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Who the study is looking for
- Patients who have signed the informed consent after receiving information about the purpose and method of this study.
- Patients with histologically and radiologically confirmed metastatic colorectal cancer (colorectal cancer) who have evaluable (measurable) lesions.
- Patients scheduled to receive their first second-line palliative chemotherapy following failure of first-line palliative chemotherapy (including those who relapse during or within 6 months after completion of postoperative adjuvant therapy, necessitating palliative chemotherapy).
- Patients who understand the research, are cooperative in the research process, and are deemed capable of participating until the completion date.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.